Phase two CD19-antibody-drug conjugate trial demonstrates promise for aggressive lymphoma
MUSC Hollings Cancer Center part of promising clinical trial for aggressive lymphomaCredit: MUSC Hollings Emma C. Vought MUSC Hollings Cancer Center was one of 28...
















